68Ga或177Lu标记DOTA-IBA作为新型骨转移诊疗一体化放射性药物的安全性与有效性:一项0/I期研究
研究纳入18例常规治疗进展的骨转移患者,比较68Ga-DOTA-IBA PET/CT与99mTc-MDP SPECT,并给予891.5±301.3 MBq 177Lu-DOTA-IBA后行系列SPECT及剂量学、安全性、疗效评估。68Ga-DOTA-IBA PET检出骨转移效能高于99mTc-MDP SPECT;骨转移灶辐射吸收剂量显著高于红骨髓、肾脏和肝脏;仅1例出现新发1级白细胞减少,骨痛缓解率82%(14/17)。
要点
- 68Ga-DOTA-IBA PET/CT检出骨转移效能高于99mTc-MDP SPECT。
- 骨转移灶吸收剂量6.40±2.13 Gy/GBq,显著高于红骨髓、肾脏和肝脏。
- 骨痛缓解率82%(14/17),仅1例新发1级白细胞减少。
核心结论
- 68Ga/177Lu-DOTA-IBA提供了一套潜在的诊疗一体化放射性药物,可能在骨转移管理中具有良好前景。
研究设计与样本
- 0/I期研究,纳入18例常规治疗下进展的骨转移患者。
- 3天内完成基线99mTc-MDP SPECT与68Ga-DOTA-IBA PET/CT对比。
- 给予891.5±301.3 MBq 177Lu-DOTA-IBA后14天内行系列177Lu-DOTA-IBA SPECT骨扫描。
- 对主要器官和肿瘤病灶行剂量学评估,通过血液生物标志物评估安全性。
- 采用Karnofsky体能状态、疼痛评分和随访68Ga-DOTA-IBA PET/CT进行疗效评估。
主要发现
- 基线68Ga-DOTA-IBA PET检出骨转移的效能高于99mTc-MDP SPECT。
- 177Lu-DOTA-IBA在骨转移灶中快速摄取并高滞留,24小时为9.43±2.75 %IA,14天为5.45±2.52 %IA。
- 肝、肾和红骨髓时间-放射性曲线显示低摄取和快速清除。
- 骨转移病灶辐射吸收剂量6.40±2.13 Gy/GBq,显著高于红骨髓0.47±0.19 Gy/GBq、肾脏0.56±0.19 Gy/GBq和肝脏0.28±0.07 Gy/GBq,所有P<0.001。
- 与基线相比,仅1例出现新发1级白细胞减少,毒性率6%。
关键数值与推荐
- 骨转移灶吸收剂量6.40±2.13 Gy/GBq显著高于红骨髓0.47±0.19 Gy/GBq、肾脏0.56±0.19 Gy/GBq和肝脏0.28±0.07 Gy/GBq,所有P<0.001。
- 177Lu-DOTA-IBA给药活度为891.5±301.3 MBq。
- 骨痛缓解率82%(14/17)。
- 8周随访68Ga-DOTA-IBA PET/CT:部分缓解3例、疾病进展1例、疾病稳定14例。
- 新发1级白细胞减少1例,毒性率6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We designed and synthesized a novel theranostic bisphosphonate radiopharmaceutical ( 68 Ga- or 177 Lu-labeled DOTA-ibandronic acid [ 68 Ga/ 177 Lu-DOTA-IBA]) for bone metastasis. In this study, the dosimetry, safety, and efficacy of 68 Ga/ 177 Lu-DOTA-IBA as a theranostic radiopharmaceutical for bone metastases were evaluated in patients with malignancy based on 68 Ga- and 177 Lu-DOTA-IBA images, blood samples, and dosimetric analysis. PATIENTS AND METHODS: Eighteen patients with bone metastasis and progression under conventional therapies were included in this study. Baseline 99m Tc-MDP SPECT and 68 Ga-DOTA-IBA PET/CT were performed for comparative purposes within 3 days. After receiving 891.5 ± 301.3 MBq 177 Lu-DOTA-IBA, serial 177 Lu-DOTA-IBA SPECT bone scan was performed over 14 days. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Karnofsky Performance Status, pain score, and follow-up 68 Ga-DOTA-IBA PET/CT were performed for response evaluation. RESULTS: Baseline 68 Ga-DOTA-IBA PET demonstrated a higher efficacy for detecting bone metastases compared with 99m Tc-MDP SPECT. The time-activity curves showed fast uptake and high retention of 177 Lu-DOTA-IBA in bone metastases (24 hours: 9.43 ± 2.75 %IA; 14 days: 5.45 ± 2.52 %IA). Liver, kidneys, and red marrow time-activity curves revealed a low uptake and fast clearance. The radiation-absorbed dose in bone metastasis lesions (6.40 ± 2.13 Gy/GBq) was significantly higher than that in red marrow (0.47 ± 0.19 Gy/GBq), kidneys (0.56 ± 0.19 Gy/GBq), or liver (0.28 ± 0.07 Gy/GBq), with all P 's < 0.001. Compared with baseline level, only one patient developed new grade 1 leukopenia (toxicity rate, 6%). The 177 Lu-DOTA-IBA therapy had no statistically significant effect on bone marrow hematopoietic function, liver function, and kidney function at any follow-up visit. Bone pain palliation was achieved in 82% (14/17) of patients. The 8-week follow-up 68 Ga-DOTA-IBA PET/CT demonstrated partial response in 3 patients, disease progression in 1 patient, and stable disease in 14 patients. CONCLUSIONS: 68 Ga/ 177 Lu-DOTA-IBA provides a set of potential theranostic radiopharmaceuticals and may have a good prospect for the management of bone metastasis.
引用
- Qiu L, Wang Y, Liu H, et al. Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases : A Phase 0/I Study. Clin Nucl Med. 2023. PMID: 36976706. doi:10.1097/RLU.0000000000004634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。